Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

personalized liposomal neoantigen-based peptide vaccine EVX-01

A personalized liposomal peptide vaccine composed of specific cancer neoepitopes, which are highly patient-specific immunogenic tumor associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration of the personalized liposomal neoantigen-based peptide vaccine EVX-01, the neoepitopes induce cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells expressing these specific TAAs.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	liposomal peptide vaccine EVX-01 liposomal peptide-based vaccine EVX-01
Code name:	EVX 01 EVX-01 EVX01

personalized liposomal neoantigen-based peptide vaccine EVX-01

Search NCI's Drug Dictionary